Securities Fraud Class Action Filed Against Insulet Over Omnipod Safety
PODD sits 17% above its 52-week low of $138.79.
Summary
A securities fraud class action lawsuit has been filed against Insulet, alleging the company misrepresented the safety of its Omnipod insulin delivery products. The suit claims undisclosed manufacturing defects led to two voluntary medical device corrections in March and May 2026, causing stock drops of 6.88% and 5.07% respectively. This follows the May 26 correction and the recent overturning of a $452 million trade secret verdict, adding legal pressure. The lead plaintiff deadline is August 31, 2026, and the case is in the District of Massachusetts.
At the time of this announcement, PODD was trading at $162.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.2B. The 52-week trading range was $138.79 to $354.88. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.